# Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

> **NCT04949256** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 864 (actual)

## Conditions studied

- Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** Cisplatin
- **DRUG:** 5-FU
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Levoleucovorin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04949256
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-28
- **Primary completion:** 2025-05-08
- **Final completion:** 2026-06-12
- **Target enrollment:** 864 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04949256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04949256, "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04949256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*